BAKER BROS. ADVISORS LP - 11 Jun 2026 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Reporting relationship
Director
Issuer ticker
ONC
Reported as of
11 Jun 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
15 Jun 2026, 16:38:06 UTC
Prior SEC filing
10 Jun 2026
Next SEC filing
18 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing

Key filing fact

BAKER BROS. ADVISORS LP filed Form 4 for BeOne Medicines Ltd. (ONC) on 15 Jun 2026.

Key facts

  • This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for BeOne Medicines Ltd. (ONC).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 15 Jun 2026, 16:38.

Change

  • Previous filing in this sequence was filed on 10 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (6)

CIK 0001263508 Primary reporting owner

BAKER BROS. ADVISORS LP

Relationship
Director
Address
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature
By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date
15 Jun 2026
CIK 0001551139

667, L.P.

Relationship
Director
Address
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date
15 Jun 2026
CIK 0001580575

Baker Bros. Advisors (GP) LLC

Relationship
Director
Address
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature
By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date
15 Jun 2026
CIK 0001363364

Baker Brothers Life Sciences LP

Relationship
Director
Address
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., /s/ Name: Scott L. Lessing, Title: President
Signature date
15 Jun 2026
CIK 0001087940

BAKER FELIX

Relationship
Director
Address
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature
/s/ Felix J. Baker
Signature date
15 Jun 2026
CIK 0001087939

BAKER JULIAN

Relationship
Director
Address
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature
/s/ Julian C. Baker
Signature date
15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,546
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F2, F3, F4, F5, F6, F7, F8, F9
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,546
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F2, F3, F4, F5, F6, F7, F8, F9
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,546
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F2, F3, F4, F5, F6, F7, F8, F9
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,546
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F2, F3, F4, F5, F6, F7, F8, F9
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,546
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F2, F3, F4, F5, F6, F7, F8, F9
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,546
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F2, F3, F4, F5, F6, F7, F8, F9
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,550
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F3, F4, F5, F6, F7, F8, F9, F10
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,550
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F3, F4, F5, F6, F7, F8, F9, F10
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,550
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F3, F4, F5, F6, F7, F8, F9, F10
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,550
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F3, F4, F5, F6, F7, F8, F9, F10
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,550
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F3, F4, F5, F6, F7, F8, F9, F10
ONC transaction

Ordinary Shares

Award

Transaction value
Shares
+18,980
Change %
+13%
Price
$0.000000*
Shares after
161,550
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F1, F3, F4, F5, F6, F7, F8, F9, F10
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F11
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F11
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F11
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F11
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F11
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F11
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F12
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F12
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F12
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F12
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F12
ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1
Date
11 Jun 2026
Ownership
Direct
Footnotes
F12
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F14
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F14
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F14
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F14
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F14
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F14
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F15
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F15
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F15
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F15
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F15
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,418
Date
11 Jun 2026
Ownership
Direct
Footnotes
F13, F15
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
730,642
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F16
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
730,642
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F16
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
730,642
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F16
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
730,642
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F16
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
730,642
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F16
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
730,642
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F16
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,068,411
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F17
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,068,411
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F17
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,068,411
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F17
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,068,411
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F17
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,068,411
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F17
ONC holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,068,411
Date
11 Jun 2026
Ownership
See Footnotes
Footnotes
F4, F5, F8, F13, F17
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 17 footnotes

Footnote F1

On June 11, 2026, BeOne Medicines Ltd. (the "Issuer") granted 18,980 restricted share units (each an "RSU") payable solely in ordinary shares ("Ordinary Shares") to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") in conjunction with his election to the board of directors of the Issuer (the "Board") pursuant to the Issuer's 2016 Share Option and Incentive Plan, as amended (the "2016 Plan"). The RSUs vest on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting of RSUs granted to a director shall cease if that director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

Footnote F2

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Ordinary Shares reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Footnote F3

Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in such securities. The Funds (as defined below) each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds (as defined below) and (ii) the Funds (as defined below), Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options"), and Ordinary Shares received upon the exercise of Share Options (i.e., no direct pecuniary interest).

Footnote F4

The Adviser serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

Footnote F5

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Footnote F6

Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

Footnote F7

The acquisitions of the RSUs on this form represent a grant to Felix J. Baker of 18,980 RSUs. This grant of 18,980 RSUs for Felix J. Baker is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities.

Footnote F8

Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons.

Footnote F9

Includes beneficial ownership of 71,279 Ordinary Shares received from vested RSUs previously granted to Michael Goller, and 71,266 Ordinary Shares received from vested RSUs previously granted to Ranjeev Krishana, in their capacity as directors of the Issuer.

Footnote F10

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares reported in column 5 of Table I directly held by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

Footnote F11

Ordinary Share held directly by Felix J. Baker.

Footnote F12

Ordinary Share held directly by Julian C. Baker.

Footnote F13

Each ADS represents 13 Ordinary Shares.

Footnote F14

American Depositary Shares held directly by Felix J. Baker.

Footnote F15

American Depositary Shares held directly by Julian C. Baker.

Footnote F16

As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Footnote F17

As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC remarks

Effective June 11, 2026, Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), was elected to the board of directors (the "Board") of BeOne Medicines Ltd. (the "Issuer"). Michael Goller and Ranjeev Krishana, full-time employees of Baker Bros. Advisors LP (the "Adviser"), did not stand for re-election to the Board and as a result their service as directors ceased. By virtue of their representation on the Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .